Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215051630> ?p ?o ?g. }
- W3215051630 endingPage "5858" @default.
- W3215051630 startingPage "5858" @default.
- W3215051630 abstract "Activating mutations in the Hh pathway underlies the development of sporadic and familial skin BCC. For these oncogenic proliferations displaying ligand-independent activation of the intracellular pathway, two molecules have been approved for therapeutic purposes: vismodegib and sonidegib. Improper Hh signalling occurs in many human tumours also via a paracrine mechanism (ligand-dependent) in which the secretion of Hh ligands by stromal cells support tumour growth. On the other hand, the mobilization of neoplastic stroma by cancer cells is sustained by the activation of Hh signalling in surrounding fibroblasts suggesting a central role of this bidirectional crosstalk in carcinogenesis. Additionally, loss-of-function mutations in the PTCH1 gene in the context of NBCCS, an autosomal dominant disorder predisposing to multiple BCCs, determine tumour permissive phenotypes in dermal fibroblasts. Here, profiling syndromic and BCC-associated fibroblasts unveiled an extraordinary similarity characterized by overexpression of several Hh target genes and a marked pro-inflammatory outline. Both cell types exposed to Hh inhibitors displayed reversion of the tumour-prone phenotype. Under vismodegib and sonidegib treatment, the Wnt/β-catenin pathway, frequently over-active in tumour stroma, resulted down-regulated by pAKT-GSK3β axis and consequent increase of β-catenin turnover. Overall, this study demonstrated that vismodegib and sonidegib impacting on fibroblast tumour supportive functions might be considered in therapy for BCC independently to the mutation status of Hh components in neoplastic cells." @default.
- W3215051630 created "2021-12-06" @default.
- W3215051630 creator A5001803606 @default.
- W3215051630 creator A5004552777 @default.
- W3215051630 creator A5020009678 @default.
- W3215051630 creator A5027263714 @default.
- W3215051630 creator A5027653977 @default.
- W3215051630 creator A5048855892 @default.
- W3215051630 creator A5049586347 @default.
- W3215051630 creator A5071841724 @default.
- W3215051630 creator A5080500839 @default.
- W3215051630 creator A5084807920 @default.
- W3215051630 date "2021-11-22" @default.
- W3215051630 modified "2023-09-30" @default.
- W3215051630 title "Evaluation of Hedgehog Pathway Inhibition on Nevoid Basal Cell Carcinoma Syndrome Fibroblasts and Basal Cell Carcinoma-Associated Fibroblasts: Are Vismodegib and Sonidegib Useful to Target Cancer-Prone Fibroblasts?" @default.
- W3215051630 cites W1552410299 @default.
- W3215051630 cites W1585922331 @default.
- W3215051630 cites W1662700259 @default.
- W3215051630 cites W1947385943 @default.
- W3215051630 cites W1963904011 @default.
- W3215051630 cites W1970915933 @default.
- W3215051630 cites W1971438578 @default.
- W3215051630 cites W1976479645 @default.
- W3215051630 cites W1977923680 @default.
- W3215051630 cites W1978153323 @default.
- W3215051630 cites W1982605205 @default.
- W3215051630 cites W1984999562 @default.
- W3215051630 cites W1988442325 @default.
- W3215051630 cites W1990453562 @default.
- W3215051630 cites W1992981977 @default.
- W3215051630 cites W1993569127 @default.
- W3215051630 cites W1999500450 @default.
- W3215051630 cites W2002355858 @default.
- W3215051630 cites W2017309361 @default.
- W3215051630 cites W2022148326 @default.
- W3215051630 cites W2027860118 @default.
- W3215051630 cites W2030484446 @default.
- W3215051630 cites W2030943228 @default.
- W3215051630 cites W2031986169 @default.
- W3215051630 cites W2032469485 @default.
- W3215051630 cites W2034606800 @default.
- W3215051630 cites W2034713105 @default.
- W3215051630 cites W2040182956 @default.
- W3215051630 cites W2040360122 @default.
- W3215051630 cites W2044616474 @default.
- W3215051630 cites W2048851591 @default.
- W3215051630 cites W2049727086 @default.
- W3215051630 cites W2053324777 @default.
- W3215051630 cites W2057775661 @default.
- W3215051630 cites W2058594499 @default.
- W3215051630 cites W2071476282 @default.
- W3215051630 cites W2072948265 @default.
- W3215051630 cites W2074985883 @default.
- W3215051630 cites W2076901752 @default.
- W3215051630 cites W2077167049 @default.
- W3215051630 cites W2079067257 @default.
- W3215051630 cites W2089372943 @default.
- W3215051630 cites W2090176557 @default.
- W3215051630 cites W2091275560 @default.
- W3215051630 cites W2093659327 @default.
- W3215051630 cites W2099118069 @default.
- W3215051630 cites W2108261167 @default.
- W3215051630 cites W2108444995 @default.
- W3215051630 cites W2117328669 @default.
- W3215051630 cites W2131928859 @default.
- W3215051630 cites W2134386050 @default.
- W3215051630 cites W2137244527 @default.
- W3215051630 cites W2141453076 @default.
- W3215051630 cites W2144790481 @default.
- W3215051630 cites W2151907359 @default.
- W3215051630 cites W2152567646 @default.
- W3215051630 cites W2155312919 @default.
- W3215051630 cites W2157376707 @default.
- W3215051630 cites W2162489686 @default.
- W3215051630 cites W2164884961 @default.
- W3215051630 cites W2166773454 @default.
- W3215051630 cites W2168610782 @default.
- W3215051630 cites W2175009205 @default.
- W3215051630 cites W2207930995 @default.
- W3215051630 cites W2254153826 @default.
- W3215051630 cites W2263390674 @default.
- W3215051630 cites W2278962466 @default.
- W3215051630 cites W2293178613 @default.
- W3215051630 cites W2328283367 @default.
- W3215051630 cites W2334149595 @default.
- W3215051630 cites W2512899508 @default.
- W3215051630 cites W2539886351 @default.
- W3215051630 cites W2550160158 @default.
- W3215051630 cites W2550854194 @default.
- W3215051630 cites W2594464065 @default.
- W3215051630 cites W2595502700 @default.
- W3215051630 cites W2600332655 @default.
- W3215051630 cites W2615693675 @default.
- W3215051630 cites W2747660904 @default.
- W3215051630 cites W2749684155 @default.
- W3215051630 cites W2755551844 @default.
- W3215051630 cites W2766051584 @default.
- W3215051630 cites W2766120026 @default.